NCT05116800 2021-12-07
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
Brown University
Phase 2 Withdrawn
Clinical Trials
4 trialsNCT04906876 2021-07-28
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
Brown University
Phase 2 Withdrawn
NCT03697824 2019-10-29
Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a
GlaxoSmithKline
Phase 2 Withdrawn
NCT02059850 2016-02-03
NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Fred Hutchinson Cancer Center
Phase 1 Withdrawn